ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines. To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery ...

Peritoneal Cancer Market Outlook 2025-2035: The 7 major Peritoneal Cancer Market are expected to exhibit a CAGR of 18.7% during 2025-2035. The peritoneal cancer market is growing, as people become ...

To date, surgery is the only potentially curative treatment for gastric cancer; however, more than two-thirds of patients have unresectable disease upon diagnosis (4). Peritoneal carcinomatosis ...

The different parts of Medicare cover cancer treatments, medications, and some types of cancer screening. However, a person will still be responsible for some of the cost, and the total out-of ...

Published in a 1976 landmark research paper by Richard Doll, Austin Hill and Richard Peto, which proved that the risk of lung cancer was 25 times higher in those who smoked more than 25 cigarettes ...

Nelmastobart (hSTC810) combined with capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A phase 1b clinical trial.

Excess body weight includes the terms ‘overweight’ and ‘obesity.’ Having excess body weight is clearly linked to an overall increased risk of cancer. According to research from the American Cancer ...

Beer bellies have been identified as a crucial factor in our cancer risk. Those not meeting the World Health Organisation guidelines on waist circumference are 11% more prone to it. The study by ...

Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition ...